Posted on March 31st, 2008 by Canadian Health in
Melanoma LACK OF EFFICACY OF ADJUVANT ISOLATED LIMB PERFUSION
Cheap generic viagra online
Isolated limb perfusion does not seem to have a role in the adjuvant treatment of patients who have high-risk melanoma of the limbs. In the recently completed EORTC/WHO adjuvant trial, patients with melanomas greater than 1.5 mm thick were randomized to WLE and observation or WLE and prophylactic hyperthermic isolated limb perfusion. A significantly decreased local recurrence rate was noted in the perfused population, but the distant disease-free survival and overall survival were the same. Thus, prophylactic perfusion using melphalan cannot be recommended.
ROLE OF ADJUVANT SYSTEMIC THERAPY FOR PATIENTS WITH MELANOMA AT HIGH RISK FOR RECURRENCE
Interferon
Advances in melanoma treatment over the past decade have evolved primarily from more detailed knowledge about prognostic factors of primary and metastatic lesions. Within the larger group of melanoma patients who undergo potentially curative treatment by surgical resection, subgroups can be identified who are at high risk for recurrence and for development of systemic metastases. Patients with melanomas 1.51 to 3.99 mm deep have a variable and intermediate risk of relapse, while patients with thick primary melanomas (more than 4 mm thick), in-transit lesions, and regional lymph node involvement are at particularly high risk: the 5-year relapse risk of these stage groupings generally exceeds 50%. Once distant metastases develop, median survival is only 6 to 9 months. The investigation of adjuvant systemic treatment that can prevent melanoma recurrence has become a critical area of investigation, focused upon either the intermediate or high-risk stage groups. The rationale and general principles for adjuvant treatment of cancer are based on the premise that treatment, whether chemotherapy or immunotherapy, is more effective when the tumor cell population is small and host immune and other resistance mechanisms are still intact. To date, randomized trials using dacarbazine, nitrosoureas, a variety of combination chemotherapy regimens, BCG, Corynebacterium parvum, transfer factor, and combinations of immunotherapy and chemotherapy have not demonstrated any advantage for treatment.
Adjuvant treatment for melanoma should be considered whenever possible within clinical research protocols that seek to improve on the results of current standard therapy in a systematic manner. Patients with a high risk of recurrence and death due to melanoma in the first several years following surgery include those patients with AJCC stage III melanoma (positive regional lymph node pathology) or those with deep primary invasion (greater than 4 mm Breslow depth). Patients in these two categories have at least a 50% chance of recurrence and death within 5 years of their diagnosis with just observation and are candidates for adjuvant trials. Investigations over the past decade have focused upon the interferons in this category of high-risk melanoma, and four trials conducted in this interval have recently been published or presented in national and international forums. The Eastern Cooperative Oncology Group has completed a trial of adjuvant therapy with high-dose IFN- alpha2b compared versus observation in stage IIb or III (AJCC) patients, the results of which have served as a pivotal basis for Food and Drug Administration (FDA) approval of IFN- alpha2b for the adjuvant treatment of high-risk melanomas. The treatment protocol adopted for this early trial is notable for its use of an initial month of daily intravenous therapy at 20 MU/m2 /d for 5 days a week for 4 weeks. This 1-month period of induction therapy was designed to deliver peak levels of circulating interferon- alpha unattainable by other routes, and was followed by 11 months of subcutaneous therapy at 10 MU/m2 three times a week, designed to sustain maximal tolerable levels of interferon in an outpatient or home therapy setting. An analysis of 280 of 287 patients for whom full data were available has demonstrated a significant prolongation of median time to relapse (1.7 versus 0.98 years, P2 = .005) and overall survival (3.8 versus 2.8 years, P2 = .047). Treatment was associated with an increment in the 5-year survival from 36% to 47%, and with an increment in the 5-year continuous relapse-free survival from 26% to 37%. These data have suggested the possibility of a curative impact of therapy with IFN- alpha2b as given in this trial. Cox multivariate analysis of this trial showed IFN therapy to be a highly significant independent prognostic factor and, after stage of disease, the most significant favorable prognostic factor.
Viagra professional online
Toxicity of this therapy is significant, with nearly ubiquitous flulike symptoms of moderate to severe degree, and the need for dose delay or attenuation in more than one-third of patients during induction, and again during the subcutaneous maintenance phase of treatment. The completion of 1 year of therapy was feasible in the majority (74%) of patients who did not experience progression. Proper attention to hematologic and hepatic function has been sufficient to avoid lethal hepatic toxicities observed early during the application of this intensive protocol. The ECOG has led an intergroup confirmatory sequel study (E1690/SWOG9111/CALGB9190) that completed accrual in mid-1995 and will require up to several years of maturity for evaluation. This protocol was designed not only to corroborate E1684 but also to test the influence of a lower dose of IFN- alpha2b, 3 MU/d given subcutaneously three times weekly for 2 years. It closed in 1995 with accrual of 642 patients. This Intergroup Trial differed from the initial trial E1684 in that lymph node dissection was no longer required for patients with T4 (greater than 4.0 mm) primary melanomas.
Posted on March 31st, 2008 by Canadian Health in
Melanoma Malignant Melanoma
ROLE OF ADJUVANT RADIATION THERAPY
Elective lymph node dissection ELND, while effectively reducing regional recurrence rates, carries varying degrees of morbidity and does not offer any survival advantage in patients with thick primary tumors. On the other hand, therapeutic dissection of pathologically involved nodes is associated with a local recurrence rate of up to 50% in patients with head and neck melanomas.
Cancer information
There is an apparent advantage in terms of local regional recurrence for adjuvant radiotherapy. The following is an update of the study with a median follow-up of 38 months. Through July, 1994, 224 patients (171 men and 52 women) were enrolled. Their ages ranged from 16 to 89 years (median: 55 years). Patients were organized into three groups. Group I consisted of 118 previously untreated patients who presented with primary lesions either greater than 1.5 mm thick or Clark level IV or V who had no palpable lymphadenopathy. Twenty-seven percent had lesions greater than 4.0 mm thick. After WLE, these patients received radiotherapy to the tumor bed and at least two echelons of the draining lymphatics of 30 Gy (Dmax ) delivered in five fractions with electron beams of appropriate energy. This group of patients had an overall 5-year actuarial rate of local regional control of 86% and a 5-year survival of 63%. It was interesting, that 71% of patients with primary lesions 1.6 to 4.0 mm thick were 5-year survivors after elective radiotherapy.
Online pharmacy blog
Group II consisted of 39 patients with previously untreated disease who presented with clinically positive lymphadenopathy. These patients mostly received postoperative radiotherapy (30 Gy Dmax delivered in five fractions over 2.5 weeks); the remainder received preoperative treatment (2 Gy Dmax delivered in four fractions over 2 weeks). These patients achieved a 5-year local regional control rate of 92% and 5-year survival of 41%, with survival being inversely proportional to the number of pathologically involved lymph nodes.
Canada drugs online
Group III consisted of 67 patients who presented with recurrent regional and/or local disease, but without evidence of distant metastases. These patients were treated in the same manner as group II patients. Their 5-year local regional control rate was 88% and survival 45%. With the addition of adjuvant radiotherapy, the local-regional control rate of group II and III patients was not affected by the number of positive nodes or extracapsular extension.
These results demonstrate that adjuvant radiotherapy, either alone in clinically node-negative patients or as a surgical adjuvant in pathologically node-positive patients, can achieve local regional control in excess of 85%. This is substantially better than rates previously reported with surgery alone in comparable patients. The radiotherapy schedule used was not associated with any significant morbidity. In total, 3 of the 224 patients treated to date have sustained mild to moderate sequelae. There has been no severe complications. Although these data are impressive, proof of a therapeutic benefit from adjuvant radiotherapy can be obtained only from a prospective randomized trial. Such a trial, based on this pilot study, has been activated by the Radiation Therapy Oncology Group (RTOG).
Since two drugs weren’t better than one, then why not try three drugs and see if that’s not better than one? Zapodian and Sella have both reported on a regimen using interleukin-2, interferon and 5-FU. This is a much more intense regimen, has to be given as an inpatient. Less intense regimens are typically given as an outpatient. They both initially reported 47% response rates. We haven’t heard much from the M.D. Anderson regimen since that, but Zapodian has consistently reported response rates in the 40% range. For lack of a better idea, this is what I treat my patients with, with metastatic disease. I use the Zapodian regimen as my initial regimen. If they fail that, then they are candidates for phase I studies. Certainly if you had a phase II trial that was ongoing or access to a phase II trial, that would be extremely appropriate treatment for patients with renal cell carcinoma as an initial treatment, reserving the interleukin-2, interferon approach for later.
Viagra professional
This is a report by a group looking at predictive factors for response to biological response modifiers and this group III here are patients with sarcomatoid histology regardless of their performance status, presence of bone metastases or whatever. In that group they had very poor response to biological based therapies. This is a summary, again from the M.D. Anderson paper, and those two patients who I mentioned earlier were then treated with a doxorubicin-containing chemotherapy and both of them actually received CY-VA-DACT which was the sarcoma regimen du jour back in the 70’s and 80’s when this data was collected. Of these eight patients, two went into complete remissions with chemotherapy and were still alive at the time that this paper was published, and they were in durable complete remission. So while sarcomatoid histology is a rare histology, it’s an important histology to be aware of because I believe some patients will have very dramatic and potentially be cured from their metastatic renal cell carcinoma with this diagnosis. This is an example of one of the patients that we treated when I was at Lombardi. This is a fellow with a sarcomatoid histology, had failed interleukin-2 and interferon and had a large mediastinal mass with pleural effusion and parenchymal lung nodule. And after the MAID chemotherapy, the mediastinal mass is gone as is the parenchymal lung disease. This patient is now – I think it’s about three years out – off treatment and continues in a complete remission.
Prostate cancer
I just want to say one word about some patients who have very poorly differentiated tumors at the time of diagnosis and have a clinically demonstrable, very rapidly progressing disease. Those patients I tend not to try to treat with immunotherapy. I think their course is just too aggressive. I’ve had some luck treating them as if they were poorly differentiated carcinomas of unknown primary. I don’t think there is anything in the literature about this yet, but just as a practical matter for you as you are out in practice, it’s something to consider.
Now there’s a study that’s still ongoing at the NIH looking at the high dose regimen versus the low dose intravenous regimen, versus the subcutaneous IL-2 regimen. And the response rates were initially thought to be fairly comparable but more recent analysis has really indicated that the high dose regimen is associated with a higher response rate and probably the more durable responses. The low dose regimens are probably not as effective, either from a response rate perspective or from a duration of response perspective.
Canadian pharmacy
The science that was driving this field for many years revolved around adoptive immunotherapy and it’s been difficult to do randomized trials using adoptive immunotherapy. Bob Figlund was able to carry out a randomized trial out of UCLA, which was a multi-center trial. Where they randomized patients to receive interleukin-2 plus the tumor-infiltrating lymphocytes around the tumor, versus interleukin-2 alone. That study showed basically no difference between the two groups. There’s also been another study using autologous lymphocyte therapy and that study was also negative for an effect. Some of the more interesting approaches, though, involves the use of mini-transplants where a high, but not typical bone marrow-type doses of chemotherapy are given, and then an allogeneic transplant is given with the idea of inducing a graft-versus-tumor response. Some of the initial data has been reported recently in JCO and this was the pattern of reconstitution in the patient that they reported on, and when they got T-cell reconstitution they started to have tumor regression which was complete. Eventually completed resolution of their disease. There’s a lot of work going on in this area. Other responses have been seen in renal cell carcinoma and this study is continuing at the NIH at the present time. These patients – if you are interested in referring somebody – this is an allogeneic program that requires a sibling as a match and there needs to be a five or six out of six match.
Order cheap cialis
Now some of the most interesting and promising preclinical data in history have revolved around this very fantastic synergy between interleukin-2 and interferon in mice. This resulted in a lot of interest in looking at this combination in the clinic. And a number of studies have been done combining interleukin-2 and interferon. This was a metaanalysis. It was done on four different studies and basically where there might have been some slight benefit for the combination, certainly the marked synergy that was seen in the preclinical models did not occur in the clinic. So, to be honest, this has been more disappointing than anything else although there is probably little reason not to combine both interleukin-2 and interferon. The results have not been what we had hoped.